Valuation: Alkem Laboratories Limited

Market Cap 624B 6.49B 5.77B 5.38B 4.91B 9.26B 9.34B 65.15B 25.25B 319B 24.38B 23.85B 1,024B P/E 2027 *
27.2x
P/E 2028 * 23.6x
Enterprise Value 611B 6.36B 5.65B 5.27B 4.8B 9.06B 9.15B 63.79B 24.72B 312B 23.86B 23.35B 1,003B EV / Sales 2027 *
3.66x
EV / Sales 2028 * 3.21x
Free-Float
38.59%
Yield 2027 *
0.95%
Yield 2028 * 1.06%
09-24 Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Chief Financial Officer CI
09-24 Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Key Managerial Personnel and Senior Management Personnel, Effective September 30, 2026 CI
09-16 Alkem Laboratories Limited Launches Neuceno for the Treatment of Partial-Onset Seizures in Adult Patients CI
09-15 Alkem Laboratories Limited Announces Appointment of Shubhadeep Sinha to Senior Management Position, Effective September 15, 2026 CI
09-08 Alkem Laboratories Limited Launches Renocia Exo, India?s First Patented Ginsenoside Exosome-Based Hair Growth Serum CI
08-14 Alkem Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026
08-14 Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-03 Alkem Laboratories Limited Announces Appointment of Rajpal Singh Rana to Senior Management Position, Effective August 03, 2026 CI
07-23 Alkem Laboratories Limited Announces Resignation of Resignation of Jitendra Singh Huda as Senior Management Personnel, Effective from July 23, 2026 CI
06-02 Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 CI
06-02 Alkem Laboratories Shows Strong Moves But Weak Follow-Through Zonebourse
05-29 Bob Capital Markets Downgrades Alkem Laboratories to Sell From Hold; Price Target is INR4,638 MT
05-29 Jefferies Adjusts Alkem Laboratories' Price Target to INR6,500 From INR6,550, Keeps at Buy MT
1 day+1.09%
1 week-1.02%
Current month+1.09%
1 month+0.19%
3 months-5.10%
6 months-0.72%
Current year-5.20%
1 week 5,110
Extreme 5110
5,306.5
1 month 5,051
Extreme 5051
5,466.5
Current year 5,051
Extreme 5051
5,933.5
1 year 5,051
Extreme 5051
5,933.5
3 years 3,447
Extreme 3447
6,439.9
5 years 2,828
Extreme 2828
6,439.9
10 years 1,455
Extreme 1455
6,439.9
Manager TitleAgeSince
President - -
President - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 44 2013-08-08
Director/Board Member 63 2008-02-10
Director/Board Member 45 2019-11-10
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%-1.02%-4.39%+44.76% 6.48B
-0.61%-3.43%+39.40%+112.31% 1,025B
-1.02%-5.60%+37.67%+65.02% 623B
+1.11%-0.58%+11.10%+77.28% 459B
+0.34%-3.01%+61.21%+40.71% 355B
-0.95%-4.05%+21.60%+39.37% 336B
-1.46%-2.89%+11.84%+24.60% 270B
-1.35%-5.43%-4.69%+8.40% 247B
-1.04%-2.79%+35.52%+51.34% 220B
-1.87%-4.10%+30.92%+95.33% 183B
Average -0.10%-3.03%+24.02%+55.91% 372.47B
Weighted average by Cap. +0.42%-3.17%+30.45%+68.88%

Financials

2027 *2028 *
Net sales 167B 1.74B 1.54B 1.44B 1.31B 2.48B 2.5B 17.43B 6.75B 85.35B 6.52B 6.38B 274B 186B 1.93B 1.72B 1.6B 1.46B 2.75B 2.78B 19.39B 7.51B 94.95B 7.25B 7.1B 305B
Net income 23.07B 240M 213M 199M 181M 342M 345M 2.41B 933M 11.79B 901M 882M 37.85B 27.02B 281M 250M 233M 212M 401M 404M 2.82B 1.09B 13.81B 1.06B 1.03B 44.33B
Net Debt -13.08B -136M -121M -113M -103M -194M -196M -1.37B -529M -6.69B -511M -500M -21.46B -28.06B -292M -259M -242M -221M -416M -420M -2.93B -1.14B -14.34B -1.1B -1.07B -46.03B
Logo Alkem Laboratories Limited
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Employees
19,346
Date Price Change Volume
26-10-01 ₹5,220.00 +1.09% 291,015
26-09-30 ₹5,163.50 -1.65% 146,577
26-09-29 ₹5,250.00 +1.45% 244,410
26-09-28 ₹5,175.00 -1.88% 101,714
26-09-25 ₹5,274.00 -0.98% 28,742
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
5,220.00INR
Average target price
5,948.55INR
Spread / Average Target
+13.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKEM Stock